MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

NEOG

9.6

+4.92%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

NEOG

9.6

+4.92%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

NEOG

9.6

+4.92%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

NEOG

9.6

+4.92%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

NEOG

9.6

+4.92%↑

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

15.19 5.71

Buy Sell

Overview

Share price change

24h

Current

Min

14.37

Max

15.26

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	5.766 63.808
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+31.49% upside

Market Stats
By TradingEconomics
Market Cap	2.6B
Previous open	9.48
Previous close	15.19

News Sentiment

By Acuity

50%

156 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 kwi 2026, 23:36 UTC

Acquisitions, Mergers, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 kwi 2026, 23:24 UTC

Hot Stocks

Stocks to Watch: Gloo, Broadcom, GitLab

14 kwi 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 kwi 2026, 21:32 UTC

Major Market Movers

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 kwi 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 kwi 2026, 22:54 UTC

Earnings

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 kwi 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 kwi 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 kwi 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 kwi 2026, 22:13 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 kwi 2026, 22:12 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 kwi 2026, 22:12 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 kwi 2026, 22:10 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 kwi 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

14 kwi 2026, 20:33 UTC

Acquisitions, Mergers, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 kwi 2026, 20:32 UTC

Hot Stocks

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 kwi 2026, 19:59 UTC

Acquisitions, Mergers, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 kwi 2026, 19:38 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 kwi 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 kwi 2026, 19:21 UTC

Market Talk

Major News Events

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 kwi 2026, 19:09 UTC

Acquisitions, Mergers, Takeovers

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 kwi 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 kwi 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

31.49% upside

12 Months Forecast

Average 20 USD 31.49%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

156 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.